Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1111/CED.14713 | ||||
| Año | 2021 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Background Psoriasis is a serious and chronic noncommunicable disease. However, the fundamental measure of disease occurrence, the incidence, has been scarcely reported globally. There are no previous studies of psoriasis incidence in Latin America. Aim To estimate the incidence rates of psoriasis in Chile during 2016 and 2017 using an administrative database, the Waiting List Repository. Methods We examined referrals of psoriasis at onset, made by physicians to dermatologists, evaluated the agreement of diagnosis, and estimated the incidence of the disease considering the eligible population at risk. Results In most cases, the referrals corresponded to incident cases of psoriasis (73.3%; 95% CI: 66.6-79.2). The national incidence rates of psoriasis were 22.1 (95% CI: 21.1-23.1) and 22.7 (95% CI: 21.8-23.6) per 100 000 person-years in 2016 and 2017, respectively. The most common type of psoriasis was the late-onset type. We observed a high variation in the figures throughout the country, with a range from 0.75 (95% CI: 0.3-1.5) per 100 000 person-years in the Metropolitan region to 164.9 (95% CI: 138.6-195.1) per 100 000 person-years in the Aysen region. Conclusion We describe for the first time the incidence of psoriasis in a Latin American country. Our findings could potentially guide collaborations to improve our global understanding of psoriasis in Latin America.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Lecaros-Cornejo, Cristobal | - |
Universidad de Chile - Chile
Dermacross Clin - Chile Psoriasis Research Centre - Chile |
| 2 | DUNSTAN-ESCUDERO, JOCELYN MARIEL | Hombre |
Universidad de Chile - Chile
|
| 3 | Villena, Fabian | Hombre |
Universidad de Chile - Chile
|
| 4 | Ashcroft, Darren M. | Hombre |
UNIV MANCHESTER - Reino Unido
Faculty of Biology, Medicine and Health - Reino Unido The University of Manchester - Reino Unido |
| 5 | Parisi, R. | - |
UNIV MANCHESTER - Reino Unido
Faculty of Biology, Medicine and Health - Reino Unido The University of Manchester - Reino Unido |
| 6 | Griffiths, C. E. M. | Hombre |
UNIV MANCHESTER - Reino Unido
The University of Manchester - Reino Unido |
| 7 | HAERTEL-GRUNDLER, STEFFEN | Hombre |
Universidad de Chile - Chile
Natl Ctr Hlth Informat Syst - Chile National Center for Health Information Systems CENS - Chile |
| 8 | Maul, Julia-Tatjana | Mujer |
Univ Hosp Zurich - Suiza
Universitätsspital Zürich, Dermatologische Klinik - Suiza |
| 9 | DE LA CRUZ-FERNANDEZ, CLAUDIA | Mujer |
Dermacross Clin - Chile
Psoriasis Research Centre - Chile |
| Fuente |
|---|
| FONDECYT |
| Fondef |
| ICM |
| CORFO |
| Fondo Nacional de Desarrollo Científico y Tecnológico |
| DAAD |
| Fondo de Fomento al Desarrollo Científico y Tecnológico |
| Novartis |
| University of Manchester |
| Deutscher Akademischer Austauschdienst |
| National Institute for Health Research (NIHR) Manchester Biomedical Research Centre |
| Institut de Cardiologie de Montréal |
| Sanofi |
| AbbVie |
| Pfizer |
| UCB |
| Meso Scale Diagnostics |
| Novartis Pharma |
| National Institute for Health Research |
| Eli Lilly and Company |
| CMM-Basal |
| UCB Pharma |
| Les Laboratories Pierre Fabre |
| Roche |
| ANID |
| Agencia Nacional de Investigación y Desarrollo |
| Manchester Biomedical Research Centre |
| International Psoriasis Council |
| Cilag |
| LEO Fondet |
| Universitätsklinikum Hamburg-Eppendorf |
| International Federation of Psoriasis Associations |
| International League of Dermatological Societies |
| Eli Lilly UK |
| Universitätsspital Zürich |
| National Institute for Health and Care Research |
| Agradecimiento |
|---|
| CL has participated in clinical trials sponsored by Pfizer and Novartis. CD has served as speaker and principal investigator to Lilly, Pfizer, AbbVie, Janssen, Novartis and Amgen. JTM has served as advisor and/or received speaking fees and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, LEO Pharma, Janssen‐Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi and UCB. CEMG reports receiving honorariums or research grants from AbbVie, Almirall, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sandoz, Sanofi and UCB Pharma. DMA reports research grants from AbbVie, Almirall, Celgene, Eli Lilly, Novartis, UCB and the Leo Foundation. The remaining authors state they have no conflict of interest. The Global Psoriasis Atlas (GPA) project is delivered by the academic project staff based at the University of Manchester and University Medical Center Hamburg‐Eppendorf. The GPA is a collaboration between three leading international organizations in the world of dermatology: the International Federation of Psoriasis Associations (IFPA), The International League of Dermatological Societies (ILDS) and the International Psoriasis Council (IPC). The GPA has been supported by grants and sponsorship from the Leo Foundation, AbbVie, Eli Lilly UK, Novartis Pharma AG, UCB and Almirall. All decisions concerning analysis, interpretation and publication are made independently of any industrial contribution. DMA and CEMG are funded in part by the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre. JD and FV are funded by CMM‐Basal AFB170001, supported by Cost Center 570111 – CIMT‐CORFO and Project U‐INICIA VID 2019 UI‐004/19. SH is funded by ICM P09–015‐F, DAAD 57220037 and 57168868, CORFO 16CTTS‐66390, Fondecyt 1181823, FONDEF 19I10334 and ANID COVID0733. JMT is an employee of USZ and holds a ‘Filling the GAP’ scholarship. |